[Treatment of neuroendocrine tumors of the digestive tract].
Neuroendocrine tumors of the digestive tract are relatively rare and comprise benign and malignant tumors. WHO classification system is based on recognized differences in morphology, function and clinical behavior. European Neuroendocrine Tumor Society(ENETS)proposed grading system and TNM classification system with disease staging for endocrine tumors of each organ which are both valid tools for prognostic stratification. The only curative therapy is the complete resection of the tumor. Endoscopic submucosal dissection(ESD)or local resection can be performed in low grade and early stage tumors; on the other hand, curative resection with lymph node dissection is recommended for neuroendocrine carcinoma. Complete surgical resection of liver metastases is associated with better long-term survival. Combination chemotherapy, such as Etoposide+Cisplatin/Carboplatin, is useful in treating unresected neuroendocrine carcinomas. Octreotide and Pasireotide (SOM230), somatostatin analogues, are reported to have the benefit of both hormonal symptom control and tumor growth suppression. Development of new effective drug is expected for the treatment of neuroendocrine tumors of the digestive tract.
Wada
Ikuo
I
Department of Gastrointestinal Surgery, Graduate School of Medcine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Shimizu
Nobuyuki
N
Seto
Yasuyuki
Y
D000969:Antinematodal Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004067:Digestive System Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis
D000969:Antinematodal Agents